Adipose tissue remodelling in obese subjects is a determinant of presence and severity of fatty liver disease
- 1 January 2021
- journal article
- research article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 37 (1), e3358
- https://doi.org/10.1002/dmrr.3358
Abstract
Aims Experimental data suggest that visceral adipose tissue (VAT) dysfunction contributes to non-alcoholic fatty liver disease (NAFLD) development in obesity, however, data on humans are limited. Aims of this study were to investigate the relationship between NAFLD and VAT morphofunctional impairment and to determine whether the extent of VAT remodelling is associated with liver damage and metabolic alterations in obesity. Methods We analysed data from 40 obese individuals candidate to bariatric surgery in whom paired intraoperative liver and omental biopsies were performed for diagnosing NAFLD and VAT inflammation by immunohistochemistry and mRNA expression studies. Results Within our study population, NAFLD was significantly associated with greater VAT CD68(+)macrophages infiltration (P= .04), fibrosis (P= .04) and impaired microvascular density (P= .03) as well as increased expression of markers of local hypoxia, apoptosis and inflammation (UNC5B, CASP7, HIF1-alpha, IL-8, MIP2, WISP-1, allP < .01). The degree of VAT inflammation correlated with the severity of hepatic injury (steatosis, inflammation, fibrosis; allP < .01) and impaired gluco-metabolic profile. Conclusions In obese patients, NAFLD is associated in a dose-dependent manner with signs of VAT remodelling, which reflect more severe clinical metabolic impairment. Our study depicts morphological alterations and novel mediators of VAT dysfunction, adding knowledge for future therapeutic approaches to NAFLD and its metabolic complications.Funding Information
- Sapienza Università di Roma
This publication has 52 references indexed in Scilit:
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of diseaseHepatology, 2017
- The epidemiology of non‐alcoholic fatty liver diseaseLiver International, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndromeThe Lancet Diabetes & Endocrinology, 2014
- The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative studyHepatology, 2011
- Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesisHepatology, 2010
- Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2010
- The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitisHepatology, 2010
- Visceral adipose tissue area is an independent risk factor for hepatic steatosisJournal of Gastroenterology and Hepatology, 2007
- Non‐alcoholic fatty liver diseaseJournal of Gastroenterology and Hepatology, 2002